The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment

Liu, YT; Liu, F; Cao, L; Xue, L; Gu, WT; Zheng, YZ; Tang, H; Wang, Y; Yao, H; Zhang, Y; Xie, WQ; Ren, BH; Xiao, ZH; Nie, YJ; Hu, RG; Wu, ZB

Wu, ZB (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Ctr Pituitary Tumor, Dept Neurosurg,Sch Med, Shanghai 200025, Peoples R China.; Hu, RG (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol,State Key Lab S, Innovat Ctr Cell Signaling Network,CAS Ctr Excell, Shanghai 200031, Peoples R China.; Wu, ZB (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou 325000, Peoples R China.; Hu, RG (corresponding author), Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Life Sci, Hangzhou 310024, Peoples R China.; Hu, RG (corresponding author), Chinese Acad Sci, CAS Key Lab Brain Connectome & Manipulat,Guangdon, Brain Cognit & Brain Dis Inst BCBDI,Shenzhen Fund, Shenzhen Inst Adv Technol,Shenzhen Hong Kong Inst, Shenzhen 518055, Peoples R China.

ACTA NEUROPATHOLOGICA, 2020; 140 (3): 377

Abstract

Pituitary adenoma (PA) is one of the most common intracranial tumors, and approximately 40% of all PAs are prolactinomas. Dopamine agonists (DAs), suc......

Full Text Link